Pulmonary disease following intravesical BCG treatment

Kesten, S; Title, L; Mullen, B; Grossman, R
September 1990
Thorax;Sep1990, Vol. 45 Issue 9, p709
Academic Journal
No abstract available.


Related Articles

  • lntravezikal BCG Lmmünoterapisi SonrasËŒ GeliÅžen Hepatit Olgusu. Akalın, Şerife; Çaylak, Selmin; Ökke, Demet; Turgut, Hüseyin // Klimik Journal / Klimik Dergisi;Aug2010, Vol. 23 Issue 2, p67 

    Intravesical bacillus Calmette-Guerin (BCG) administration is used as a treatment method in superficial bladder cancer and is generally well tolerated. Side effects following BCG are usually mild and self-limiting and serious systemic side effects are rarely seen. BCG-related hepatitis is a rare...

  • BCG.  // Reactions Weekly;5/4/2013, Issue 1451, p10 

    The article describes the case of a 48-year-old man who developed a systemic granulomatous reaction following intravesical treatment with BCG.

  • BCG.  // Reactions Weekly;8/25/2012, Issue 1416, p13 

    The article describes the case of a 63-year-old man who developed granulomatous prostitis following treatment with intravesical BCG instillation for bladder cancer.

  • Bladder Cancer: Current Optimal Intravesical Treatment. Lamm, Donald L.; McGee, William R.; Hale, Kaye // Urologic Nursing;Oct2005, Vol. 25 Issue 5, p323 

    The article presents information about the treatment of bladder cancer by using intravesical bacillus Calmette-Guerin (BCG) immunotherapy. This therapy with a three week maintenance schedule is the best treatment for the high-risk tumors. Side effects of BCG immunotherapy can be decreased by...

  • BCG.  // Reactions Weekly;Mar2015, Vol. 1544 Issue 1, p46 

    The article presents case report of a patient who developed BCG sepsis with bacteraemia, then disseminated pulmonary BCG, after receiving intravesical BCG immunotherapy.

  • Is intravesical bacillus Calmette-Guerin safe and efficacious in steroid treated and immunocompromized patients. Kumar, Santosh; Kekre, Nitin S. // Indian Journal of Urology;Jul-Sep2006, Vol. 22 Issue 3, p286 

    It is generally assumed that intravesical bacillus Calmette-Guerin (BCG) should be avoided in the setting of immunosuppression. This retrospective study[1] from the Memorial Sloan-Kettering Cancer Center was undertaken to assess the safety and efficacy of intravesical BCG instillation in 24...

  • Intravesical therapy of urinary bladder tumours. Soukup, Viktor; Čapoun, Otakar; Pešl, Michael; Feherová, Zuzana; Hanuš, Tomáš // Czech Urology / Ceska Urologie;2014, Vol. 18 Issue 2, p85 

    According to current guidelines, intravesical treatment should be off ered to every patient with non-muscle invasive bladder cancer. Th e type of intravesical therapy should be based on the risk of recurrence and progression. In patients with low risk Ta tumours, a single intravesical...

  • Implications of Isoniazid Resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for Immunotherapy in Bladder Cancer. Watts, Matthew R; Taylor, Peter C; Sintchenko, Vitali; Whelan, Clair M; Farnsworth, Robert H; Jones, Philip; Jelfs, Peter; Carr, David; Goldberg, Hazel // Clinical Infectious Diseases;Jan2011, Vol. 52 Issue 1, p86 

    We report a case of sepsis from Mycobacterium bovis Bacillus Calmette-Guérin (BCG) with low-level isoniazid resistance following intravesical treatment for bladder cancer. Isoniazid resistance in BCG has therapeutic implications when it causes infections after intravesical instillation. For...

  • Peritoneal tuberculosis presenting as recurrent peritonitis secondary to treatment with intravesical Bacillus Calmette-Guérin in a patient receiving peritoneal dialysis. Iqbal, Junaid; Raja, Maria; Leung, Janson // Clinical Kidney Journal;Feb2015, Vol. 8 Issue 1, p107 

    Intravesical Bacillus Calmette-Guérin (BCG) is an established treatment for high-risk superficial bladder cancer [Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors.1976. J Urol 2002; 167: 891-893, Lamm DL, van der Meijden...

  • Epirubicin: A Review of its Intravesical Use in Superficial Bladder Cancer. Onrust, S.V.; Wiseman, L.R.; Goa, K.L. // Drugs & Aging;1999, Vol. 15 Issue 4, p307 

    The anthracycline epirubicin has been investigated for intravesical use in patients with superficial bladder cancer. In multicentre, randomised trials, prophylaxis with intravesical epirubicin 30 to 80mg after transurethral resection (TUR) was more effective than no prophylaxis in the prevention...


Read the Article


Sign out of this library

Other Topics